Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 10 , ISSUE 1 ( January-April, 2021 ) > List of Articles


Anti-CD6 Humanized Monoclonal Antibody Itolizumab, Halts Disease Progression and Severity of Acute Respiratory Distress Syndrome in COVID-19 Disease: A Case Study

Hemant P. Thacker, Amit Dhekane, Nivedita Wadhwa, Shalaka Patil

Keywords : Acute respiratory distress syndrome, CD6, COVID-19, cytokine storm, hyperinflammation, itolizumab

Citation Information : Thacker HP, Dhekane A, Wadhwa N, Patil S. Anti-CD6 Humanized Monoclonal Antibody Itolizumab, Halts Disease Progression and Severity of Acute Respiratory Distress Syndrome in COVID-19 Disease: A Case Study. Indian J Respir Care 2021; 10 (1):112-115.

DOI: 10.4103/ijrc.ijrc_78_20

License: CC BY-NC-SA 4.0

Published Online: 06-12-2022

Copyright Statement:  Copyright © 2021; Indian Journal of Respiratory Care.


In COVID-19 patients, cytokine release syndrome plays a critical role in disease progression. Itolizumab inhibits T-cell proliferation and differentiation, thereby modulating imminent cytokine storm. Here, we report a case of a 44-year-old male patient with confirmed COVID-19 and oxygen saturation (SpO2) of 88% on room air. A chest X-ray revealed dense opacification. High levels of inflammatory markers such as C-reactive protein (CRP) and ferritin were observed. The patient's SpO2 decreased to 87% on day 4 despite the best supportive care. Itolizumab was then administered at 1.6 mg/kg along with high flow oxygen. The patient's SpO2 values improved to 95% and 97% on 4th- and 5th-day postinfusion, respectively. CRP and ferritin levels decreased by 85.96% and 24.48%, respectively, along with radiological improvement. The patient was discharged on the 7th day postinfusion in a clinically stable condition. This is the first report of an anti-CD6 humanized monoclonal antibody, itolizumab, given to a patient with moderate-to-severe COVID-19 disease that showed a reduction in hyperinflammation, leading to clinical and radiological improvement.

  1. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol 2020;20:363-74.
  2. Rodriguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, et al. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results Immunol 2012;2:204-11.
  3. Menon R, David BG. Itolizumab-A humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clin Cosmet Investig Dermatol 2015;8:215-22.
  4. Jayaraman K. Biocon's first-in-class anti-CD6 mAb reaches the market. Nat Biotechnol 2013;31:1062-3.
  5. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: A model-based analysis. Lancet Infect Dis 2020;20:669-77.
  6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4.
  7. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis 2020;96:467-74.
  8. Facciorusso A, del Prete V, Antonino M, Neve V, Crucinio N, di Leo A, et al. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J Gastroenterol Hepatol 2014;29:1905-10.
  9. WHO R&D Blueprint: Novel Coronavirus. COVID-19 Therapeutic Trial Synopsis. Available from: [Last accessed on 2020 Jun 23].
  10. Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, et al. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol 2014;71:484-92.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.